Cellectar Biosciences: A Pivotal Year for Regulatory Submissions and Pipeline Expansion

Cellectar US15117F8077

The year 2026 represents a critical period for Cellectar Biosciences as it advances its radiopharmaceutical pipeline toward key commercial and clinical milestones. The company’s strategy hinges on navigating significant regulatory pathways while expanding its research into new oncology areas.

Central to Cellectar’s near-term objectives is the development of its lead asset, Iopofosine I-131, and the strategic broadening of its clinical portfolio. The company is positioning its proprietary Phospholipid Drug Conjugate (PDC) platform for potential commercialization, with several important events scheduled:

• The dosing of the first patient in a Phase 1b study for CLR 125 in breast cancer is slated for the first quarter of 2026.
• Initial interim Read more...